Safety and Immunogenicity Study of Inactivated Nasal Influenza Vaccine NB-1008 Administered by Sprayer

Healthy Adult Volunteers Clinical Trial

Official title:

A Phase 1 Randomized, Observer-Blind, Controlled, Safety, Tolerability and Immunogenicity Study of Intranasal NB-1008 in Healthy Adult Volunteers Administered by Nasal Sprayer and Pipette

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01354379
• Other study ID #: NB-1008-002
• Status: Completed
• Phase: Phase 1
• First received: May 13, 2011
• Last updated: March 26, 2013
• Start date: May 2011
• Est. completion date: July 2012

Study information

• Verified date: March 2013
• Source: NanoBio Corporation
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to test the safety and immune response of a new intranasal vaccine against influenza, called NB-1008. The vaccine is composed of a licensed vaccine that is normally given as an injection, called Fluzone, and an adjuvant (additive that helps a vaccine work better), called W805EC. In a prior clinical study this vaccine showed promising results in terms of being well tolerated and eliciting mucosal and systemic immune responses after administration by a dropper. In this study NB-1008 is being administered by dropper as well as a nasal sprayer to determine if the sprayer further enhances the immune response.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 125
• Est. completion date: July 2012
• Est. primary completion date: June 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 49 Years

Eligibility

Inclusion Criteria:

1. Male or female.

2. Are 18-49 years of age, inclusive.

3. If female, must be non-pregnant as confirmed by a negative serum pregnancy test conducted at screening and a negative urine pregnancy test conducted at the site within 24 hours preceding receipt of vaccine.

4. Females who are not surgically sterile or at least one year post-menopausal agree to use oral, implantable, transdermal or injectable contraceptive or another reliable form of contraception approved by the Investigator for a minimum of 30 days prior to vaccination and for 3 months following vaccination.

5. Healthy, as determined by medical history, physical examination, vital signs, and clinical laboratory examinations.

6. Comprehension of the study requirements, expressed availability for the required study period, and ability to attend scheduled visits.

7. Has given written informed consent to participate in the study.

Exclusion Criteria:

1. Presence of significant acute or chronic, uncontrolled medical or psychiatric illness (institution of new medical or surgical treatment, or a significant dose alteration for uncontrolled symptoms or drug toxicity within 3 months). Subjects with a history of chronic cough, frequent sinus infections, sinusitis, allergic rhinitis, nasal polyps or obstruction, including deviated septum significant enough to obstruct the nasal openings are to be excluded. Subjects with seasonal rhinitis may be included if their 'season' does not occur within 3 months of the vaccination date and they are not currently receiving intranasal steroids.

2. Receipt of the 22010-2011 influenza vaccine or the 2009 pandemic H1N1 influenza vaccine.

3. Positive serology for HIV-1 or HIV-2, or HCV antibodies.

4. Platelet count <150,000/mm3.

5. Positive urine drug screen.

6. History of aspiration, dysphagia, swallowing disorders, stroke or other neurologic conditions that may predispose the subject to aspiration of test articles into the respiratory tract.

7. History of Bell's palsy.

8. Cancer or treatment for cancer, within 3 years. Subjects with a history of cancer who are disease-free without treatment for 3 years or more are eligible. Basal cell carcinoma (BCC) or (SCC) are allowed, unless present on or near the nose.

9. Impaired immune responsiveness, regardless of cause, including diabetes mellitus.

10. Presently receiving or history of receiving any medications or treatments that affects the immune system such as immune globulin, interferon, immunomodulators, cytotoxic drugs or drugs known to be frequently associated with significant major organ toxicity, or systemic corticosteroids (oral or injectable) in the past 6 months.

11. Chronic use of inhaled or intranasal sprays including decongestants and corticosteroids.

12. Presently a smoker or tobacco user or have a history of smoking or tobacco use within the past year prior to screening.

13. Receipt or planned administration of a nonstudy vaccine within 30 days before the study, including licensed influenza vaccines and prior to the Day 60 telephone contact. Immunization on an emergency basis with Tetanus Toxoids Adsorbed for adult use (Td or Tdap) up to 8 days before or at least 8 days after a dose of study vaccine will be allowed. Administration of study vaccine can be delayed if a nonstudy vaccine has been administered and will be given as soon as acceptable, as described above.

14. Known allergy to any vaccine component, including eggs, egg products, or thimerosal.

15. History of allergic and/or anaphylactic type reaction to injected vaccines or to any of the components of NB-1008 [soybean oil, dehydrated alcohol (anhydrous ethanol), polysorbate (Tween 80) and cetylpyridinium chloride (CPC)].

16. History of drug or chemical abuse in the year before the study.

17. Receipt of any investigational product or nonregistered drug within the 30 days before study entry or currently enrolled in any investigational drug study or intends to enroll in such a study within the ensuing 6 month period.

18. Use of nasally administered prescription or over-the-counter (OTC) medications within 7 days before vaccination

19. Receipt of blood or blood products 8 weeks before study entry or planned administration prior to the Day 60 telephone contact.

20. Donation of blood or blood products within 8 weeks before study entry or at any time up to the Day 28 clinic visit.

21. Acute disease within a week prior to vaccination, defined as the presence of a moderate or severe illness (as determined by the investigator through medical history and physical examination) with or without fever. For subjects with a minor illness, such as diarrhea, or mild upper respiratory tract infection with or without low-grade febrile illness, the subject can be re-screened once they have complexly recovered.

22. Any condition that, in the opinion of the investigator, might interfere with study objectives.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Healthy Adult Volunteers

Intervention

Biological:
• NB-1008
NB-1008 is composed of Fluzone containing 15 micrograms (mcg) of strain-specific hemagglutinin (HA) and 20% W805EC adjuvant.
• Fluzone IN
The active control is Fluzone containing 15 micrograms (mcg) of strain-specific hemagglutinin (HA).

Locations

Country	Name	City	State
United States	Johnson County Clin-Trials	Lenexa	Kansas

Sponsors (1)

Lead Sponsor	Collaborator
NanoBio Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and Tolerability	Number of Participants with Adverse Events (AE) collected through Day 28 and Serious Adverse Events (SAE) collected through Day 365.	365 Days	Yes
Secondary	Systemic Humoral Immune Response	Serum hemagglutination-inhibition (HAI) Geometric Mean Titer (GMT) and proportion of Volunteers with >=4 fold increase in titer as well as proportion of volunteers with titer >= protective level of 40	Day 28 and Day 60	No
Secondary	Systemic Cell Mediated Immune Response	Stimulation Index (SI) of antigen-specific proliferation and cytokine secretion of peripheral mononuclear cells (PBMC)	Day 28	No
Secondary	Mucosal Immune Response	Nasal wash anti-Fluzone IgA Geometric Mean Titer (GMT) and proportion of volunteers with >=4 fold increase in GMT anti-Fluuzone IgA titer	Day 14 and Day 28	No